Research

He informed that the government is planning to set up three national CoEs for drugs, medical devices in the country and NIPER…

Phase II trial to commence on August 6, 2020

It reports a reduction of hospitalisation by 28 per cent

I-SPY COVID will evaluate the impact of cenicriviroc, otezla, and firazyr on inflammatory response in severely ill, hospitalised…

Existing drugs that inhibit the complement system could help treat patients with severe disease

It will test its vaccine candidate in more than 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and…

It reduced the risk of cardiovascular death or hospitalisation for heart failure versus placebo on top of standards of care in…

Bolt’s Boltbody Immune Stimulating Antibody Conjugate (ISAC), BDC-1001, is currently in a first-in-human Phase 1/2 clinical study…

The study is expected to include about 120 sites globally and up to 30,000 participants

The DBT-BIRAC supported trial aims to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes…